KWKyle D. Wood

Kyle D. Wood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyle D. Wood has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endogenous oxalate synthesis in mouse models of metabolic dysfunction-associated steatotic liver disease

    by Xingsheng Li, Owen P. Cunneely, Jeremy B. Foote, Zachary R. Burns, Sonia Fargue, Dean G. Assimos, John Knight, Kyle D. Wood

    Metabolic dysfunction-associated steatotic liver disease (MASLD) has been reported to lead to increased oxalate synthesis in mouse models. We show here that changes in oxalate synthesis, mediated by complex changes in enzymes involved in glyoxylate metabolism, are dependent on the degree of severity of MASLD, resulting in limited increases in urinary oxalate in mild MASLD, but marked increases in steatohepatitis.

  • Open Access

    Is 3 cm the upper limit of stone size for effective steerable ureteroscopic renal stone evacuation?

    by Wei-Jen Chen, Feres Camargo Maluf, Hannah Jarvis, Zachary Burns, Vicente Elorrieta, Joseph Crivelli, Thomas Chi, Dean G. Assimos, Kyle D. Wood

    Purpose: The CVAC ® Aspiration System is a novel device designed to actively evacuate stone fragments during ureteroscopy. While recent studies have validated its safety, the precise upper limit of stone size for this treatment is undefined. We aimed to determine the ideal size and volume thresholds using CVAC for steerable ureteroscopic renal evacuation (SURE) procedures. Methods: A retrospective, observational study of patients undergoing SURE procedures by a single surgeon between August 2023 and April 2025 was undertaken. Stone size and volume were quantified using preoperative CT imaging. The primary outcome was stone-free status, based on Endourological Society criteria for CT, or <5 mm for ultrasound/X-ray. Receiver Operating Characteristic (ROC) curve analyses were performed to estimate optimal cut-off values for stone size and volume. Results: Stones in 55 kidneys of 50 patients were removed with this approach. The majority had significant medical co-morbidities (82% ASA Class 3 or 4). The median stone size was 24.0 mm, and the overall stone-free rate (SFR) was 63.6%. For stones smaller than 2 cm, the SFR was 95.7%. ROC analysis identified a stone size of 30.9 mm (AUC 0.895) and a volume of 1501.1 mm³ (AUC 0.834) as predictive cut-offs for clearance. The volume threshold increased to 2264.6 mm³ with utilization of the CVAC 2.0 device. The overall complication rate was 12%, without any high-grade complications. Conclusions: The SURE procedure with the CVAC device may be effective for treating patients with stones up to 3 cm in size or volumes less than 2200 mm³. Well-designed, randomized prospective studies are needed to confirm these findings.

  • Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?

    by Owen P. Cunneely, Anne Roberts, Sonia Fargue, John Knight, Dean G. Assimos, Kyle D. Wood

    Purpose of review: Metabolic dysfunction associated steatotic liver disease (MASLD) is increasing throughout the world, affecting nearly one in three individuals. Kidney stone disease, which is also increasing, is associated with MASLD. Common risk factors for both, including obesity, diabetes, dyslipidemia, hypertension, and metabolic syndrome, are likely drivers of this association. We present here a review of the associations and possible interconnections between these two common disease processes. Recent findings: Epidemiological studies are discordant regarding the impact of sex on this association and on the impact of MASLD on incident stone risk. The nature of kidney stones is rarely taken into account. A favorable milieu for uric acid kidney stone formation may be created by a lower urine pH resulting from defective ammonium production associated with insulin resistance, common in MASLD. Endogenous oxalate synthesis, a major risk factor for calcium oxalate kidney stones, may be increased in MASLD via decline in the activity of enzymes involved in the detoxification of glyoxylate, the immediate precursor of oxalate. Summary: The nature of kidney stones associated with MASLD and factors driving this association remain to be elucidated. Potential mechanisms identified underlying this include an increase in the risk factors for both uric acid and calcium oxalate kidney stones.


  • Open Access

    How We Treat Primary Hyperoxaluria Type 1

    by Matthew C. Breeggemann, Peter C. Harris, John C. Lieske, Gregory E. Tasian, Kyle D. Wood

    An abstract is unavailable. This article is available as a PDF only.


  • Obesity and Pediatric Nephrolithiasis

    by Henry J. Paiste, Kevin Narang, Pankaj P. Dangle, Dean G. Assimos, Kyle D. Wood

  • Progress with RNA Interference for the Treatment of Primary Hyperoxaluria

    by Kathryn Sawyer, Stephen Leahy, Kyle D. Wood

    Over the last few years, US Food and Drug Administration-approved drugs using RNA interference have come to the market. Many have treated liver-specific diseases utilizing N-acetyl galactosamine conjugation because of its effective delivery and limited off-target effects. The autosomal recessive disorder primary hyperoxaluria, specifically type 1, has benefited from these developments. Primary hyperoxaluria arises from mutations in the enzymes involved in endogenous oxalate synthesis. The severity of disease varies but can result in kidney failure and systemic oxalosis. Until recently, the treatment options were limited and focused primarily on supportive treatments, pyridoxine use in a subset of patients with primary hyperoxaluria type 1, and liver-kidney transplants in those who progressed to kidney failure. Two genes have been targeted with RNA interference; lumasiran targets glycolate oxidase and nedosiran targets lactate dehydrogenase A. Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process. Unfortunately, despite initial hopes that nedosiran may also be a treatment option for primary hyperoxaluria types 2 and 3, initial data suggest otherwise. The use of RNA interference liver-specific targeting for the treatment of primary hyperoxaluria type 1 will likely transform the natural history of the disease.


  • Open Access

    Generation of a GLO-2 deficient mouse reveals its effects on liver carbonyl and glutathione levels

    by Xingsheng Li, Sonia Fargue, Anil Kumar Challa, William Poore, John Knight, Kyle D. Wood


  • Open Access

    Is There an Association between Childhood Obesity and Pediatric Kidney Stone Disease? A Literature Review

    by Henry J. Paiste, Luke Moradi, Dean G. Assimos, Kyle D. Wood, Pankaj P. Dangle

    Objectives: To examine the most recent literature and published science in determining any and all possible associations between pediatric obesity and pediatric urolithiasis. Methods: Retrospective literature review of pediatric stone formers with diagnosed stone disease and all associated risk factors. Peer-reviewed, published manuscripts from the past several decades were analyzed for risk factors associated with pediatric obesity such as diet, hypertension, and renal diseases. Comparing the pediatric obesity literature with the pediatric stone forming literature, any associations and correlations were derived and analyzed. Results: Despite the existing evidence that obesity is linked to stones in adults, the evidence remains unclear whether obesity plays a role in children. Nutritional discrepancies, in the setting of the obesity epidemic, have been shown to alter the risk profile of pediatric patients. Consistent with the published literature, and lack of consistent correlation with obesity and stone disease, is the knowledge that age, gender, geography, and climate may all play a role in the onset of pediatric obesity and may also be on the causal pathway toward pediatric urolithiasis. Conclusion: The manuscript demonstrates that there are a number of risk factors, congenital or acquired, that are associated with pediatric obesity. The mechanisms responsible for these associations may be on the causal pathway toward childhood urolithiasis. These mechanisms that underlie these associations need to be further investigated.


  • Open Access

    Contribution of Dietary Oxalate and Oxalate Precursors to Urinary Oxalate Excretion

    by Joseph J. Crivelli, Tanecia Mitchell, John Knight, Kyle D. Wood, Dean G. Assimos, Ross P. Holmes, Sonia Fargue

    Kidney stone disease is increasing in prevalence, and the most common stone composition is calcium oxalate. Dietary oxalate intake and endogenous production of oxalate are important in the pathophysiology of calcium oxalate stone disease. The impact of dietary oxalate intake on urinary oxalate excretion and kidney stone disease risk has been assessed through large cohort studies as well as smaller studies with dietary control. Net gastrointestinal oxalate absorption influences urinary oxalate excretion. Oxalate-degrading bacteria in the gut microbiome, especially Oxalobacter formigenes, may mitigate stone risk through reducing net oxalate absorption. Ascorbic acid (vitamin C) is the main dietary precursor for endogenous production of oxalate with several other compounds playing a lesser role. Renal handling of oxalate and, potentially, renal synthesis of oxalate may contribute to stone formation. In this review, we discuss dietary oxalate and precursors of oxalate, their pertinent physiology in humans, and what is known about their role in kidney stone disease.